Method
Each article starts from the primary literature, not from other websites. For CJC-1295 that is the ConjuChem chemistry paper of 2005 and the two Journal of Clinical Endocrinology and Metabolism trials of 2006; for ipamorelin it is the Novo Nordisk paper of 1998, the pharmacokinetic study of 1999 and the phase 2 trials registered by Helsinn; for the GHRH plus GHRP principle it is the 1990 study by Bowers and Thorner. Abstracts are read from PubMed; registry entries are read from the ClinicalTrials.gov API. When a figure is quoted, it is the figure in the abstract or the registry entry, in the units the authors used.
Before publication, every DOI on the site is requested from the CrossRef API at api.crossref.org and every trial number from the ClinicalTrials.gov API; a reference that does not return HTTP 200 is not cited. As of the last check, the site cites 34 sources, 26 of them with a DOI and 5 with a registry number. Regulatory statements point to the FDA and WADA pages they come from.
What the site will not do
- It gives no usage information of any kind. It reports what the published studies measured, with the DOI beside each figure.
- It does not publish testimonials, reviews, before-and-after accounts or personal results, because none exist in the literature for these molecules and inventing them would be a lie.
- It does not describe effects on the body: the studies it cites measured hormone levels and kinetics, and the site reports those figures only.
- It carries no analytics, no advertising pixel and no third-party script.
Why it links to OXpeptides
The OXpeptides link on every page goes to its CJC-1295 / ipamorelin guide at oxpeptides.com; the blend is sold there for research use only, lyophilized and shipped within Europe with tracked delivery.
Corrections
Errors are corrected on the page where they occur, with the updated date changed, and a note is added at the foot of the page when the correction changes a figure. Reports go to contact@cjc-1295-ipamorelin.com; a report that cites a DOI or an NCT number is answered first. The full policy is on the editorial policy page.
Who
The site is written and maintained by its editorial desk. It does not publish personal bylines: every article is signed by the editorial desk, whose page lists what it reads, how it checks each reference and every guide it maintains. Corrections and questions go to the address above.
All 4 guides
- CJC-1295 DAC vs no DAC (2026)9 min read
- Sermorelin vs CJC-1295 ipamorelin (2026)10 min read
- CJC-1295 peptide: from a ConjuChem bench to two human trials10 min read
- Tesamorelin ipamorelin vs CJC-1295 ipamorelin (2026)8 min read
Informational content, not medical advice. CJC-1295 and ipamorelin are investigational research compounds, not approved by the FDA or the EMA for any use, sold for research use only, not for human or veterinary use.